Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Lymphoma Clinical Trial

Official title:

A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02932280
• Other study ID #: 16-878
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2016
• Est. completion date: October 2024

Study information

• Verified date: May 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 14
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 21 Years

Eligibility

Inclusion Criteria:

• Diagnosis: Pathologic confirmation of solid tumor, including central nervous system tumor or lymphoma.
• Recurrent or Refractory Disease for which no further effective standard treatment is available.
• Patient must have failed at least one prior therapy.
• All patients must have evaluable disease as defined as:
• Solid tumors must have a lesion evaluable by RECIST criteria version 1.1;
• Central nervous system tumors will be evaluated by RANO criteria.
• Available tissue to perform protein and genomic analysis
• Age:
• Phase 1: = 3 and = 21 years of age at time of enrollment
• Phase 2: = 3 and = 21 years of age at diagnosis
• Body Surface Area requirements varied by dose level:

Dose Level BSA (m2)

• 1 = 0.82

1. = 0.66

2. = 0.52

3. = 0.45

• Performance level:
• Lansky score = 60% (patients < 16 years of age)
• Karnofsky score = 60% (patients = 16 years of age)
• Cardiac Function: Patients must have a shortening fraction = 27% or left ventricular ejection fraction = 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA).
• Negative ß-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential = 7 days before starting neratinib therapy.
• Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product. Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product.
• Written informed consent/assent prior to any study-specific procedures.
• Patient must be able to swallow tablet or have existing gastrostomy feeding tube to enable administration of tablet.
• Patients must have recovered from the acute toxic effects of all prior therapy to = grade 1 before entering this study.

Exclusion Criteria:

• Prior treatment within the following timeframes:
• Systemic chemotherapy or biologic therapy = 2 weeks or 5 half lives (t ½) of the agent used, whichever is shorter, prior to the start of neratinib
• Radiation therapy outside the central nervous system = 14 days prior to neratinib
• Radiation to the central nervous system = 12 weeks prior to initiation of neratinib
• Patients with previous allogeneic stem cell transplant (SCT) if they meet either of

the following criteria:

• 60 days from allogeneic SCT
• Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD
• Inadequate marrow function in Cohort 1:
• Absolute neutrophil count < 1.0 x 10^9 /L
• Platelets < 100 x 10^9 /L
• Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
• Total bilirubin > 1.5 X the upper limit of normal (ULN) for age
• AST (SGOT) and ALT (SGPT) > 3 X ULN (unless attributed to disease involvement)
• Serum creatinine > 1.5 X ULN for age or creatinine clearance = 60mL/min/1.73m^2
• Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days (or decreasing dose of corticosteroid) are eligible to participate in the study.) Patients with primary central nervous system tumors are eligible.
• Clinically active cardiac disease, including prolonged QTc interval = 481ms (i.e. = grade 2)
• Pregnant or breast-feeding women
• Being actively treated for a concurrent malignancy with the exception of basal cell carcinoma or carcinoma in situ of the cervix.
• Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, unexplained fever > 38.5°C (101.3°F) or psychiatric illness/social situation that would limit compliance with study requirements.
• Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade = 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).
• Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease
• Known history of hepatitis C or known active hepatitis B infection
• Known hypersensitivity to any component of the investigational product

Related Conditions & MeSH terms

• Central Nervous System Neoplasms
• Central Nervous System Tumor
• Leukemia
• Lymphoma
• Neoplasms
• Nervous System Neoplasms
• Solid Tumor

Intervention

Drug:
• Neratinib
Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).

Locations

Country	Name	City	State
Canada	Alberta Children'S Hospital	Calgary	Alberta
United States	Pennsylvania State Hershey Children's Hospital	Hershey	Pennsylvania
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Arnold Palmer Hospital for Children	Orlando	Florida
United States	Stanford University School of Medicine and Stanford Cancer Institute	Palo Alto	California
United States	Phoenix Children'S Hospital	Phoenix	Arizona
United States	Huntsman Cancer Institue	Salt Lake City	Utah
United States	University of Texas	San Antonio	Texas

Sponsors (8)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Alberta Children's Hospital, Arkansas Children's Hospital Research Institute, M.D. Anderson Cancer Center, Milton S. Hershey Medical Center, Phoenix Children's Hospital, Stanford University, University of Texas

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the number of patients who have experienced Dose Limiting Toxicity	NCI CTCAE Version 4.0.Definition of Hematologic Dose-Limiting Toxicity (solid tumor cohort only) Any hematologic toxicity as indicated: Febrile neutropenia defined as Grade 3 or 4 neutropenia with fever = 38.5°C and /or infection requiring antibiotic or antifungal treatment Grade 4 neutropenia lasting > 7 days Grade 4 thrombocytopenia lasting > 7days Any drug-related adverse experience, regardless of grade, leading to a dose reduction of a study drug. Non-Hematologic Dose-Limiting Toxicities: Non-hematologic dose-limiting toxicity will be defined as any Grade 3, 4 or 5 nonhematologic toxicity with the specific exception of: Any grade diarrhea that occurs in the setting of poor compliance with supportive measures that last for < 48 hours Any grade dehydration related to diarrhea that occurs in the setting of inadequate compliance to supportive care measures that last for < 48 hours.	1 year

External Links

•   Memorial Sloan Kettering Cancer Center